Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Spark Therap (NQ: ONCE )

N/A USD UNCHANGED
Last Price Updated: 12:31 PM EST, Dec 17, 2019 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Spark Therap

< Previous 1 2 3 4 5 6 Next >
Analysis: Positioning to Benefit within Real Goods Solar, Natural Resource Partners LP, Spark Therapeutics, Social Reality, Rapid7, and BiondVax Pharmaceuticals — Research Highlights Growth, Revenue,
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Real Goods Solar, Inc.... 
From GlobeNewswire News Releases
European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations
Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that the European Commission has... 
From GlobeNewswire News Releases
Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for... 
From GlobeNewswire News Releases
Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Nov. 6,... 
From GlobeNewswire News Releases
Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA® (voretigene neparvovec-rzyl) at American Academy of Ophthalmology Annual Meeting
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced findings from three post-hoc... 
From GlobeNewswire News Releases
Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the launch of Eye Want 2 Know, a... 
From GlobeNewswire News Releases
Detailed Research: Economic Perspectives on Cerus, AdvanSix, Spark Therapeutics, Imperva, Central Garden & Pet, and Francesca's — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cerus Corporation... 
From GlobeNewswire News Releases
Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate
Data from IND-enabling studies in three species support moving SPK-3006 into the clinic in 2019 
From GlobeNewswire News Releases
Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease today announced that the Committee for Medicinal... 
From GlobeNewswire News Releases
Report: Exploring Fundamental Drivers Behind Fiesta Restaurant Group, Emerge Energy Services LP, Collegium Pharmaceutical, Cutera, Resources Connection, and Spark Therapeutics — New Horizons, Emerging
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fiesta Restaurant Group,... 
From GlobeNewswire News Releases
Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for... 
From GlobeNewswire News Releases
Spark Therapeutics Recognized for Second-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has been named one of Philadelphia’s... 
From GlobeNewswire News Releases
Spark Therapeutics to Host Conference Call on Tuesday, Aug. 7 at 8:30 a.m. ET to Discuss Second Quarter Results and Recent Business Highlights
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Aug. 7, 2018, at 8:30... 
From GlobeNewswire News Releases
Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy
Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evaluate the efficacy and safety of... 
From Business Wire News Releases
Analysis: Positioning to Benefit within Second Sight Medical Products, ICF International, Morningstar, Spark Therapeutics, Natera, and Kadmon — Research Highlights Growth, Revenue, and Consolidated Re
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Second Sight Medical... 
From GlobeNewswire News Releases
Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer (NYSE:PFE), today announced that, with a cumulative... 
From GlobeNewswire News Releases
Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress
Achieved historic milestone with first patients treated with LUXTURNA™ (voretigene neparvovec-rzyl) 
From GlobeNewswire News Releases
Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, May 8, 2018, at 8:30... 
From GlobeNewswire News Releases
Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA COMMS, Westinghouse Air Brake Technologies, and Resource Capital — What Drives Growth in Today's Co
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Vitamin Shoppe, Inc... 
From GlobeNewswire News Releases
Spark Therapeutics Sells Priority Review Voucher for $110 Million
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced it has entered into an agreement to sell its... 
From GlobeNewswire News Releases
Pre-Market Technical Scan on Biotech Equities -- Sorrento Therapeutics, Spark Therapeutics, Synthetic Biologics, and TG Therapeutics
From PR Newswire
Report: Exploring Fundamental Drivers Behind Accelerate Diagnostics, FTI Consulting, Spark Therapeutics, Achaogen, Oxford Industries, and Kronos Worldwide — New Horizons, Emerging Trends, and Upcoming
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Accelerate Diagnostics,... 
From GlobeNewswire News Releases
Spark Therapeutics to Participate in Multiple Conferences in March
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that Arlene V. Drack, M.D., associate professor... 
From GlobeNewswire News Releases
Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress
U.S. Food and Drug Administration (FDA) grants breakthrough therapy designation to SPK-8011 for hemophilia A 
From GlobeNewswire News Releases
Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Feb. 20, 2018, at 8:30... 
From GlobeNewswire News Releases
Stock Review for Biotech's Investors -- Spark Therapeutics, Synthetic Biologics, TG Therapeutics, and Zosano Pharma
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ONCE, SYN, TGTX, and ZSAN which can be accessed for free by signing up to... 
From PR Newswire
Spark Therapeutics to Participate in Multiple Conferences in February
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that members of company management or... 
From GlobeNewswire News Releases
Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced it has entered into a licensing agreement with... 
From GlobeNewswire News Releases
Report: Exploring Fundamental Drivers Behind United Fire Group, Almost Family, Spark Therapeutics, Veracyte, Ruth's Hospitality Group, and IDT — New Horizons, Emerging Trends, and Upcoming Development
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of United Fire Group, Inc... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that Robert J. Perez, a long-time... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.